CN EN
Insights
IDD Explained: An Interview with BioDuro-Sundia’s Head of Integrated Drug Discovery Services, Dr. Frank Ruebsam
Integrated drug discovery (IDD) describes an approach where companies utilize an external service provider (CRO, CDMO, or integrated CRDMO such as BioDuro-Sundia) to perform all steps of a new drug di
November 10, 2023
Q&A: How a highly clinically translatable NASH model helps new drug discovery
The industry restores confidence in NASH new drug R&D with Madrigal Pharmaceuticals’ submission of a rolling review for Resmetirom in this July and the rise of GLP-1 receptor agonists treatments for NAFLD/NASH, e.g., Semaglutide for NASH at Phase III from Novo Nordisk; Tirzepatide for NASH at Phase II from Eli Lilly; Efinopegdutide for NAFLD at Phase 2a from MSD, etc.
November 03, 2023
Q&A: Building new models for preclinical in vivo immuno-oncology efficacy studies
BioDuro-Sundia is proud to highlight the Head of Oncology Dr. Phillip Wang’s insights on the topic of Building New Models for Preclinical In vivo Immuno-Oncology Efficacy Studies and welcome you to explore BioDuro-Sundia Oncology Services.
July 25, 2023
Q&A: Process chemistry for IND filing support
BioDuro-Sundia is proud to highlight the Head of Process R&D Qixuan Lu’s insights on the topic of Process chemistry for IND filing support and welcome you to explore BioDuro-Sundia Process Chemistry Services.
May 06, 2023
FAQ: Controlled release
​Controlled release is a drug delivery mechanism that allows for the gradual release of a drug into the body over a specific period of time.
March 11, 2023
Solution Engine 2.0
Our upgraded platform utilizes only mg amounts of API to screen amorphous solid dispersion technologies and now has extra screening capabilities for controlled and delayed release formulations.
March 11, 2023
Strategic control of genotoxic impurity in innovative drug development
BioDuro-Sundia is proud to highlight leading researcher Dr. Jingli Wang’s insights on the topic of strategic controls on genotoxic impurities in process development, and welcome you to explore BioDuro-Sundia Process Research and Development Services.
March 11, 2023
Benefits of using a CRDMO
CRDMOs are staffed by trained professionals who are experienced in working with clinical research data.
March 11, 2023
Large Molecule Bioanalysis Services
BioDuro-Sundia’s large molecule bioanalysis DMPK/ADME platform provides representative research services to a variety of molecular modalities including mAbs, ADC, oligonucleotides, large or small molecule biomarkers or metabolites, proteins and peptides.
View more
We use necessary cookies to ensure our website functions properly and to keep it secure. These necessary cookies must be enabled. By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. You can personalize or withdraw your consent at any moment by clicking on the link "Cookies Settings". For more information on how we use cookies, including the total lifespan of cookies and the identity of third parties intervening on our website, please consult the Privacy Notice available in the site footer.
Accept all